Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Acute severe diarrhea related to plerixafor use.

Sargın G, Yavaşoğlu I, Coşkun A, Kadıköylü G, Bolaman Z.

Turk J Gastroenterol. 2013;24(4):370. No abstract available.

2.

Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.

Flomenberg N, Comenzo RL, Badel K, Calandra G.

Biol Blood Marrow Transplant. 2010 May;16(5):695-700. doi: 10.1016/j.bbmt.2009.12.538. Epub 2010 Jan 11.

3.

Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization.

Tricot G, Cottler-Fox MH, Calandra G.

Bone Marrow Transplant. 2010 Jan;45(1):63-8. doi: 10.1038/bmt.2009.130. Epub 2009 Jun 22.

PMID:
19543330
4.

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).

Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Blade J, Lonial S, Dimopoulos MA, Einsele H, Barlogie B, Anderson KC, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV, Durie BG; IMWG.

Leukemia. 2009 Oct;23(10):1904-12. doi: 10.1038/leu.2009.127. Epub 2009 Jun 25.

PMID:
19554029
5.

Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.

Nademanee AP, DiPersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ, Hsu FJ, Bridger G, Bolwell BJ.

Biol Blood Marrow Transplant. 2012 Oct;18(10):1564-72. doi: 10.1016/j.bbmt.2012.05.017. Epub 2012 Jun 6.

6.

Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.

Stewart DA, Smith C, MacFarland R, Calandra G.

Biol Blood Marrow Transplant. 2009 Jan;15(1):39-46. doi: 10.1016/j.bbmt.2008.10.018.

7.

Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.

Harvey RD, Kaufman JL, Johnson HR, Nooka A, Vaughn L, Flowers CR, Khoury HJ, Lechowicz MJ, Langston AA, Lonial S, Waller EK.

Biol Blood Marrow Transplant. 2013 Sep;19(9):1393-5. doi: 10.1016/j.bbmt.2013.06.003. Epub 2013 Jun 10.

8.

The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF.

D'Addio A, Curti A, Worel N, Douglas K, Motta MR, Rizzi S, Dan E, Taioli S, Giudice V, Agis H, Kopetzky G, Soutar R, Casadei B, Baccarani M, Lemoli RM.

Bone Marrow Transplant. 2011 Mar;46(3):356-63. doi: 10.1038/bmt.2010.128. Epub 2010 May 31.

PMID:
20577218
9.

Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.

Lor KW, Helmons PJ, Belew H, Lane JR, Ball ED.

Pharmacotherapy. 2012 Jul;32(7):596-603. doi: 10.1002/j.1875-9114.2012.01096.x.

PMID:
22760691
10.

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.

Hübel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S, Christopeit M, Bogner C, Galm O, Hartwig R, Heits F, Lordick F, Rösler W, Wehler D, Zander AR, Albert MH, Dressler S, Ebinger M, Frickhofen N, Hertenstein B, Kiehl M, Liebler S, von Lilienfeld-Toal M, Weidmann E, Weigelt C, Lange F, Kröger N.

Bone Marrow Transplant. 2011 Aug;46(8):1045-52. doi: 10.1038/bmt.2010.249. Epub 2010 Oct 25.

PMID:
20972470
11.

Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.

Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, Badel K, Dehner C, Gibney C, Bridger G, Calandra G.

Bone Marrow Transplant. 2010 Jan;45(1):39-47. doi: 10.1038/bmt.2009.119. Epub 2009 Jun 1.

PMID:
19483760
12.

Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.

Fruehauf S, Ehninger G, Hübel K, Topaly J, Goldschmidt H, Ho AD, Müller S, Moos M, Badel K, Calandra G.

Bone Marrow Transplant. 2010 Feb;45(2):269-75. doi: 10.1038/bmt.2009.142. Epub 2009 Jul 13.

PMID:
19597422
13.

Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.

Milone G, Martino M, Spadaro A, Leotta S, Di Marco A, Scalzulli P, Cupri A, Di Martina V, Schinocca E, Spina E, Tripepi G.

Br J Haematol. 2014 Jan;164(1):113-23. doi: 10.1111/bjh.12606. Epub 2013 Oct 21.

PMID:
24138497
14.

Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma.

Lanza F, Lemoli RM, Olivieri A, Laszlo D, Martino M, Specchia G, Pavone V, Imola M, Pasini A, Milone G, Scortechini I, Todisco E, Guggiari E, Cascavilla N, Martinelli G, Rambaldi A, Bosi A.

Transfusion. 2014 Feb;54(2):331-9. doi: 10.1111/trf.12265. Epub 2013 Jun 19. Erratum in: Transfusion. 2014 Jun;54(6):1688-91.

PMID:
23781769
15.

G-CSF plus plerixafor (Mozobil) to mobilize hematopoietic stem cells in patients with thrombocytopenia or leukopenia prior to auto-SCT.

Micallef IN, Jacobsen ED, Shaughnessy P, Gandhi PJ, Calandra G, van Rhee F, Uberti J.

Bone Marrow Transplant. 2013 Feb;48(2):303-4. doi: 10.1038/bmt.2012.125. Epub 2012 Jul 9. No abstract available.

PMID:
22773123
16.

[Mobilisation of haematopoietic stem cells with plerixafor--secondary publication].

Hansen PB, Gaarsdal E.

Ugeskr Laeger. 2009 Nov 2;171(45):3272-5. Review. Danish.

PMID:
19887056
17.

A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure.

Lefrère F, Mauge L, Réa D, Ribeil JA, Dal Cortivo L, Brignier AC, Aoun C, Larghéro J, Cavazzana-Calvo M, Micléa JM.

Transfusion. 2013 Mar;53(3):564-9. doi: 10.1111/j.1537-2995.2012.03744.x. Epub 2012 Jun 21.

PMID:
22725259
18.

Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.

Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ, Langston A, Prichard JM, Anderson D, Gleason C, Lonial S, Flowers CR, Kaufman JL, Waller EK.

Transfusion. 2011 Oct;51(10):2175-82. doi: 10.1111/j.1537-2995.2011.03136.x. Epub 2011 Apr 14.

PMID:
21492180
19.

Current status of stem cell mobilization.

Gertz MA.

Br J Haematol. 2010 Sep;150(6):647-62. doi: 10.1111/j.1365-2141.2010.08313.x. Review.

PMID:
20636438
20.

Mobilization, collection, and transplantation of peripheral blood hematopoietic progenitor cells in a patient with multiple myeloma and hemoglobin SC disease.

Tormey CA, Snyder EL, Cooper DL.

Transfusion. 2008 Sep;48(9):1930-3. doi: 10.1111/j.1537-2995.2008.01777.x. Epub 2008 May 29.

PMID:
18513256

Supplemental Content

Support Center